Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

Detailed price information for Tvardi Therapeutics Inc (TVRD-Q) from The Globe and Mail including charting and trades.

Five-agent AI team could speed clinical trial design using real-world patient records

An artificial intelligence system that operates like a collaborative team of medical experts could accelerate clinical trial ...
News-Medical.Net

Collaborative AI system helps accelerate clinical trial design

An artificial intelligence system that operates like a collaborative team of medical experts could accelerate clinical trial design, one of the most difficult steps in drug development, according to a ...
The Manila Times

Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis

Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital peer-reviewed papers: the discovery-to-clinic journey in Nature Biotechnology, and ...